Quality & complianceOfficial

Health Canada flags Type III recall of Neogen Vet's Uniprim Oral Powder over packaging defect

🇨🇦 Health Canada · Wed 04 Nov 2026

Nine lots of the apple-flavoured veterinary powder are affected by a defect that may compromise container closure integrity, with national distribution down to retail level.

Health Canada has published a recall of Neogen Vet Uniprim Oral Powder (Apple Flavored) after identifying a packaging defect in nine lots. The notice was first published on 3 November 2026 and updated the following day.

According to the regulator, the defect may compromise container closure integrity in the affected lots. The product is a powder containing sulfadiazine 333 mg/g and trimethoprim 67 mg/g, authorised under DIN 02241375. It is listed in the category of veterinary drugs.

The affected lot numbers are CAUP0128261CC, CAUP0202261CC, CAUP0203261CC, CAUP0421261CC, CAUP0422261CC, CAUP0423261CC, CAUP0825261CC, CAUP0826261CC and CAUP0827261CC. Distribution was national, and the recall depth covers retailers, wholesalers and healthcare establishments.

Health Canada classifies the action as Type III under identification number RA-82895. The recalling firm is Neogen Corporation of Lexington, Kentucky. As general context, a Type III recall generally denotes a situation where the product is not expected to cause adverse health consequences. The notice advises users to verify whether their product is affected and to consult their healthcare provider before discontinuing use of an affected product or if they have any health concerns. It also directs questions about the recall to the recalling firm and asks for side effects or other safety complaints to be reported to Health Canada.

What it means for your team

  • Check inventory and distribution records against the nine listed lot numbers for DIN 02241375.
  • Quality teams should note that the stated issue is a container closure integrity concern, not a reported problem with the active ingredients.
  • Wholesalers, retailers and healthcare establishments are within the recall depth and should act on the notice.
  • Side effects and other safety complaints linked to the product should be reported to Health Canada.

Official source: Health Canada ↗

Article written by VigiEye from the official source (Health Canada). AI-assisted; check the source before acting.

More Quality & compliance All →